hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06386770, orgStudyIdInfo id: Asw.U./742 /2/23, briefTitle: Systemic Versus Local Dexmedetomidine as An Adjuvant to Bupivacaine in Ultrasound Guided Erector Spinae Block, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Aswan University, class: OTHER, descriptionModule briefSummary: The aim of this study is to investigate the analgesic effect of local versus systemic dexamedetomedine as adjuvant to bupivacaine in erector spinae block in kidney exploration surgeries., conditionsModule conditions: Erector Spinae Block, conditions: Dexmedetomidine, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: These prospective, randomized, controlled clinical trials will be performed in Aswan University Hospital on 75 patients who are scheduled for kidney exploration surgeries, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, maskingDescription: In our randomized controlled trial, we employed masking (also called blinding) to reduce bias. Participants were unaware of whether they were receiving the intervention or control. Caregivers were instructed not to reveal this information, and outcome assessors who evaluated results were kept separate from intervention delivery., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 75, type: ESTIMATED, armsInterventionsModule interventions name: Dexmedetomidine Injection [Precedex], interventions name: Bupivacaine Hydrochloride, interventions name: Dexmedetomidine in 0.9 % NaCl 200 Mcg/50 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML), outcomesModule primaryOutcomes measure: The duration of analgesia, this was defined as the time in minutes to the first request for postoperative analgesics., secondaryOutcomes measure: 2. Total postoperative opioid consumption (Nalbuphine consumption (mg) within the 48-hour period ., secondaryOutcomes measure: Ramsay Sedation Scale (RSS) (1: anxious; 2: cooperative and tranquil; 3: responding to command; 4: brisk response to stimuli; 5: sluggish response to stimuli; and 6: no response to stimuli) will be all assessed, secondaryOutcomes measure: Intraoperative hemodynamic parameters blood pressure, secondaryOutcomes measure: Minimum alveolar concentration (MAC) requirements, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Aswan University, status: RECRUITING, city: Aswan, zip: 81511, country: Egypt, contacts name: soudy S hammad, role: CONTACT, phone: +201014761523, email: soudi.salah@aswu.edu.eg, contacts name: tarek S hemaida, role: CONTACT, phone: 01007363190, email: dr.tarek@aswu.edu.eg, contacts name: Rehab A Mahmoud, MSc, role: SUB_INVESTIGATOR, geoPoint lat: 24.09082, lon: 32.89942, hasResults: False
protocolSection identificationModule nctId: NCT06386757, orgStudyIdInfo id: Asw.U. 911/3/24, briefTitle: Incidence Of Nasal and Oropharyngeal Bleeding: Video Laryngoscopy Versus Direct Laryngoscopy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Aswan University, class: OTHER, descriptionModule briefSummary: The objective of this study is to compare the effectiveness and safety of video laryngoscopy versus direct laryngoscopy for nasal intubation in patients with maxillofacial fractures regarding less bleeding to oral and nasal structures, quicker intubation times, increased success rates for first intubation attempts, fewer uses of the Magill forceps and the less need for cervical spine extension, conditionsModule conditions: Maxillofacial Injuries, conditions: Nasal Bleeding, conditions: Intubation Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: These prospective, randomized, controlled clinical trials will be conducted at Aswan University Hospital on 62 patients who are scheduled for maxillofacial surgeries requiring nasal intubation., primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 64, type: ESTIMATED, armsInterventionsModule interventions name: Combined Video Laryngoscopy (VL) and Bougie, interventions name: Combined Direct Laryngoscopy (DL) and Bougie, outcomesModule primaryOutcomes measure: Incidence of nasal and oropharyngeal bleeding, secondaryOutcomes measure: Time of successful intubation, defined as the time from removal of mask ventilation and beginning of bougie insertion until inflation of tube cuff, secondaryOutcomes measure: Overall rate of first trial success., secondaryOutcomes measure: The use of magill forceps, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Aswan University, status: RECRUITING, city: Aswan, zip: 81528, country: Egypt, contacts name: Soudy S Hammad, MD, role: CONTACT, phone: +201014761523, email: soudi.salah@aswu.edu.eg, contacts name: Mohammed E Yahia, MSc, role: CONTACT, phone: 01125257916, contacts name: Mohammed A Alazhary, MD, role: SUB_INVESTIGATOR, geoPoint lat: 24.09082, lon: 32.89942, hasResults: False
protocolSection identificationModule nctId: NCT06386744, orgStudyIdInfo id: DUS-AUBD-01, briefTitle: Dusquetide for the Treatment of Behcet's Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07, primaryCompletionDateStruct date: 2025-02, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Soligenix, class: INDUSTRY, descriptionModule briefSummary: This is a clinical study to see if dusquetide can treat flares of oral and genital ulcers caused by Behcet's Disease. Study participants will receive an infusion of dusquetide twice a week for 4 weeks (8 treatments total), with weekly follow-up visits for an additional 4 weeks., conditionsModule conditions: Behçet Disease, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Dusquetide, outcomesModule primaryOutcomes measure: Number of Oral Ulcers, primaryOutcomes measure: Number of Genital Ulcers, secondaryOutcomes measure: Pain of Oral Ulcers, secondaryOutcomes measure: Pain of Genital Ulcers, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Istanbul University - Cerrahpasa, Cerrahpasa School of Medicine, city: Istanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06386731, orgStudyIdInfo id: SYNEO-01, briefTitle: Continuous Versus Intermittent Phototherapy in Treatment of Neonatal Jaundice, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-07-05, primaryCompletionDateStruct date: 2022-11-25, completionDateStruct date: 2023-04-28, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Goztepe Prof Dr Suleyman Yalcın City Hospital, class: OTHER, descriptionModule briefSummary: One of the most common diseases in the neonatal period is indirect hyperbilirubinemia (IHB). After phototherapy was discovered accidentally in 1958, it has been used as the most effective treatment method for IHD for more than 60 years. Sources that provide phototherapy are developing rapidly technologically. However, there is no clearly defined usage table in the literature for applying phototherapy with faster effects and fewer side effects. In recent years, the use of intermittent phototherapy has been recommended with similar effectiveness. Phototherapy has significant side effects such as dehydration, diarrhea, chromosome breaks, retinal damage, skin rashes, hypocalcemia, thrombocytopenia. As phototherapy exposure decreases, its side effects decrease.In our study; We plan to find the most ideal method in the treatment of IHB by comparing intermittent PT with continuous phototherapy in terms of effectiveness. We aim to achieve the best bilirubin reduction and minimal side effects with less exposure to phototherapy., conditionsModule conditions: Neonatal Jaundice, conditions: Phototherapy Complication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This was a single-center, with block randomisation \[1:1\], open-label, parallel group study., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 225, type: ACTUAL, armsInterventionsModule interventions name: Intermittent Phototherapy, outcomesModule primaryOutcomes measure: Comparison of the effectiveness of CPT and IPT, secondaryOutcomes measure: Comparison of side effect frequency of CPT and IPT, eligibilityModule sex: ALL, minimumAge: 1 Day, maximumAge: 15 Days, stdAges: CHILD, contactsLocationsModule locations facility: Göztepe Prof. Dr. Suleyman Yalcin City Hopital, city: Kadıköy, state: İstanbul, zip: 34730, country: Turkey, geoPoint lat: 40.62015, lon: 29.22536, hasResults: False
protocolSection identificationModule nctId: NCT06386718, orgStudyIdInfo id: USG for ped art can, briefTitle: Ultrasonographic Evaluation of Arteries of the Hand in Pediatric Patients, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-15, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2025-05-01, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Ankara University, class: OTHER, descriptionModule briefSummary: Ultrasound measurements of the ulnar artery and radial artery at different angles are obtained and compared to determine the optimal diameters for possible arterial cannulation in pediatric patients., conditionsModule conditions: Ulnar and Radial Artery, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 184, type: ESTIMATED, outcomesModule primaryOutcomes measure: Determining the Diameter and Depth at different angles, primaryOutcomes measure: Comparing Ulnar and Radial Artery Diameters Across Age Groups, eligibilityModule sex: ALL, maximumAge: 10 Years, stdAges: CHILD, contactsLocationsModule locations facility: Ankara University School Of Medicine, status: RECRUITING, city: Ankara, zip: 06100, country: Turkey, contacts name: Zeynep Altinbas, MD, role: CONTACT, phone: +905356082156, email: szpostalcioglu@gmail.com, contacts name: Ozlem S Can, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Zeynep S Altinbas, MD, role: SUB_INVESTIGATOR, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06386705, orgStudyIdInfo id: TSN084-101CH, briefTitle: A Study of TSN084 in Patients With Advanced Malignant Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-07-20, primaryCompletionDateStruct date: 2025-09-30, completionDateStruct date: 2026-03-30, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Tyligand Bioscience (Shanghai) Limited, class: INDUSTRY, descriptionModule briefSummary: TSN084 is a novel type II kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This phase 1a/1b study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies in China., conditionsModule conditions: Malignant Neoplasm, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 114, type: ESTIMATED, armsInterventionsModule interventions name: TSN084, outcomesModule primaryOutcomes measure: Dose limiting toxicity (DLT), primaryOutcomes measure: Incidence of Treatment-Emergent Adverse Events (TEAE), secondaryOutcomes measure: Maximum plasma concentration (Cmax), secondaryOutcomes measure: Time to Cmax (Tmax), secondaryOutcomes measure: Area under the concentration versus time curve from time 0 to the last measurable concentration (AUC 0-t), secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Duration of response (DoR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Time to response (TTR), secondaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Overall survival (OS), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Cancer Hospital Chinese Academy of Medical Sciences, status: RECRUITING, city: Beijing, state: Beijing, zip: 100021, country: China, contacts name: Jie Wang, MD, PhD, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, locations facility: Peking university cancer hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100142, country: China, contacts name: Minglei Zhuo, MD, role: CONTACT, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06386692, orgStudyIdInfo id: Aarhus111, briefTitle: Community Based Promotion of Physical Activity in Nepal (COBIN-PA), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-10-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: University of Aarhus, class: OTHER, descriptionModule briefSummary: Globally, one in four adults does not meet the WHO-recommended level of physical activity. Insufficient physical activity is the fourth leading risk factor, contributing to 9% of global premature mortality. PA is effective in weight management, cardiorespiratory fitness, and increasing quality of life. However, there is lack of evidence on effectiveness on promoting physical activity in community level. The aim of the study is to test the effectiveness of Female Community Health Volunteers (FCHVs)-led community-based educational program on physical activity promotion in community level. This is an open label cluster-randomized controlled trial with 1:1 allocation where FCHVs will deliver a family-based education for the promotion of physical activity at community level in Nepal. The intervention package will be guided by Theory of planned behavior and will contain home-based interactive health education sessions focused on increasing PA in a household setting. FCHVs will use resource materials for health education. The mixed-effect linear regression model will determine the adjusted interaction between time and intervention. The results of this study will show the changes in the mean moderate to vigorous physical activity minutes per day due to time intervention interaction. The evidence generated from this study will help to provide new knowledge on the community-based promotion of Physical Activity and its effectiveness for policymakers and researchers. It will hopefully support the attainment of the national and global target of reducing insufficient physical activity., conditionsModule conditions: Exercise, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 264, type: ESTIMATED, armsInterventionsModule interventions name: FCHVs-led community based educational physical activity intervention, outcomesModule primaryOutcomes measure: Mean moderate to vigorous physical activity, eligibilityModule sex: ALL, minimumAge: 19 Years, maximumAge: 69 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06386679, orgStudyIdInfo id: R016634005, briefTitle: Amniotic Fluid Mesenchymal Stem Cells Developed for Chondrogenic Treatment (AFCC) Injection in Elderly Knee Osteoarthritis Patients, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-08-17, primaryCompletionDateStruct date: 2023-11-23, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Siriraj Hospital, class: OTHER, descriptionModule briefSummary: Amniotic fluid mesenchymal stem cells developed for chondrogenic treatment (AFCC) are used to treat elderly patients suffering from knee osteoarthritis (OA). The injection reduces inflammation and promotes the recovery of knee function, leading to an improved quality of life., conditionsModule conditions: Knee Osteoarthritis, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Ten elderly patients from both gender diagnosed with knee osteoarthritis, will be enrolled according to specific inclusion and exclusion criteria. These patients will be injected with amniotic fluid mesenchymal stem cells developed for chondrogenic treatment. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: allogenic amniotic fluid mesenchymal stem cell, outcomesModule primaryOutcomes measure: Incidence of abnormal physical examination, primaryOutcomes measure: Incidence of abnormal vital sign, primaryOutcomes measure: Incidence of abnormal laboratory test results, primaryOutcomes measure: Incidence of abnormal ECG parameters, primaryOutcomes measure: The type of Adverse event (AE), numbers of AE and proportion of patients with AE., secondaryOutcomes measure: Pain score, secondaryOutcomes measure: Knee Injury and Osteoarthritis Outcome Score (KOOS), secondaryOutcomes measure: Degree of cartilage change, eligibilityModule sex: ALL, minimumAge: 60 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Siriraj Hospital, city: Bangkok Noi, state: Bangkok, zip: 10700, country: Thailand, geoPoint lat: 13.76266, lon: 100.47798, hasResults: False
protocolSection identificationModule nctId: NCT06386666, orgStudyIdInfo id: RLRL-CTP, briefTitle: A Clinical Trial to Evaluate the Safety and Efficacy of Single-use Fibrous Ring Sutures for the Suture of Fibrous Ring Incision After Nucleus Pulposus Removal, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-04-29, completionDateStruct date: 2025-07-15, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Suzhou Kerui Medical Technology Co., Ltd, class: OTHER, descriptionModule briefSummary: The objective of this clinical trial was to evaluate the safety and effectiveness of single-use annular sutures for the closure of annular incisions after nucleus pulposus removal. Participants used single-use annular sutures to close the annular fibers. The success rate of suture, reduction value of annulus, proportion of annulus reduction, intraoperative blood loss, suture time, VAS pain score (low back, bilateral lower extremities), Oswestry index (ODI index), and Short were evaluated The effectiveness evaluation results of Form-12 health survey (SF-12 score), treatment success rate, device defects, product operation satisfaction, and safety evaluation results of recurrence rate, adverse events, and serious adverse events were used to verify the safety and effectiveness of disposable fibrillar suture for annular incision suture after nucleus pulposus removal., conditionsModule conditions: Intervertebral Disc Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 135, type: ESTIMATED, armsInterventionsModule interventions name: Disposable fibrous ring sutures, outcomesModule primaryOutcomes measure: Success rate of suture, secondaryOutcomes measure: Annulus fibril cleft decreased in value, secondaryOutcomes measure: Reduced proportion of annular fibril cleft, secondaryOutcomes measure: Intraoperative blood loss, secondaryOutcomes measure: Suture time, secondaryOutcomes measure: Treatment success rate, secondaryOutcomes measure: VAS pain score (lower back, bilateral lower limbs), secondaryOutcomes measure: SF-12 rating, secondaryOutcomes measure: ODI index, otherOutcomes measure: Recurrence rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False